ABSTRACT
M
ore than 20 million individuals in the United States have asthma, and asthma attacks account for 1.7 million emergency visits and 440,000 hospitalizations per year. 1 The 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, developed by the National Heart, Lung, and Blood Institute (NHLBI), describes six steps of therapy. 2 The goal of asthma therapy is disease control, which comprises current impairment and future risk. Impairment assesses the frequency and severity of symptoms; the use of rescue inhalers; lung function; and functional limitations. Risk assesses the probability of whether a patient will have future exacerbations. When asthma is not controlled, Expert Panel Report 3 (EPR3) recommends increasing the intensity of, or "stepping up" therapy. 2 Although the care recommended in EPR3 has similarities to current standards, there are significant differences. Current asthma care may have to change to be brought in line with these guidelines; the degree of change needed is not known.
Evaluating care in relation to guidelines can be difficult and time-consuming. A method for using administrative claims for evaluating what step of therapy an asthma patient uses would simplify this process. We developed an algorithm to identify therapy step using administrative claims and used the algorithm to examine how physicians changed therapy in response to evidence of poor control. The goal was to assess care at baseline, before attempts were made to align care with EPR3. We focused on the extent to which increases in current practices regarding therapeutic intensity, use of oral corticosteroids (OCS), and use of specialist care would have to be modified to fit the new guidelines.
METHODS
This was a cohort study that used administrative claims to develop an algorithm to identify therapy step among asthma patients and to examine whether therapy step increased among asthma patients whose disease was not well controlled. We used the Ingenix i3 LabRx database, a Health Insurance Portability and Accountability Act-compliant administrative claims database of 8 -10 million covered lives. This database contains adjudicated pharmacy and medical claims submitted by providers, health care facilities, and pharmacies. Claims include information on each physician visit, medical procedure, hospitalization, drug dispensed, and test performed. Also available are member enrollment and benefit information as well as limited patient, provider, and hospital demographic information. All major regions of the United Statets are represented in the data. The study was exempt from review by the human subjects protection committee.
Subjects
We identified patients 12-64 years old with evidence of uncontrolled asthma during the identification pe- Using the EPR3 definitions and published studies as a guide, we defined uncontrolled asthma as the presence of either risk or impairment. We defined "impairment" to be present if a patient filled prescriptions for seven or more SABA in 1 year 2, 3 and "risk" to be present if a patient had two or more of the following events: an asthma-related ED visit, an asthma-related hospitalization, and an OCS fill that occurred within 7 days of a physician visit. 2 For patients with impairment, the index date was the date of their seventh SABA fill (the date on which they met the definition of impairment). For patients with risk, the index date was the date of the second asthma exacerbation. We excluded patients who were not continuously enrolled during the year before and after the index date. We also excluded patients with cystic fibrosis (ICD-9: 277.xx), chronic obstructive pulmonary disease (ICD-9: 491.2, 493.2, 496.x, and 506.4), emphysema (ICD-9: 492.x, 506.4, 518.1, and 518.2), bronchopulmonary dysplasia (ICD-9: 770.7), and those who were pregnant during the study period.
Variables
All baseline measures were determined in the 1-year preindex period. Demographic measures included age, gender, and region of residence. Clinical measures included asthma-related comorbidities (e.g., sinusitis, rhinitis, and tonsillitis); evidence of allergy, determined using claims for relevant diagnoses and treatments; and asthma risk stratification, determined using a previously validated three-level system. 4 We also examined nonasthma-related acute or chronic conditions. For acute conditions, we used Clinical Classifications Software, a validated method developed by the Agency for Health Care Research and Quality, to cluster patient diagnoses into broad disease categories. 4 We counted the number of chronic conditions using the method of Hwang et al. 5 Utilization measures included the number of physician visits (classified as primary care, allergist, pulmonologist, or other), the use of asthma-related medication during the 6 months before the index date, and the specialty of each patient's usualcare physician. 6 A usual-care physician was categorized as primary care, allergist, pulmonologist, or other. Patients assigned to "other" included those with usual care from specialties not generally associated with asthma care (e.g., cardiology and dermatology) and those for whom a usual-care physician could not be assigned because of missing specialty information.
We developed and tested a claims-based algorithm to identify therapy step. The algorithm defined steps according to EPR3 and added two additional categories, "no asthma treatment" and "undefined" (see Appendix). Undefined was defined as asthma treatment combinations not matching a guideline step. In practice, care may be changed at any time, but in commercially insured populations, many medications are filled only every 3 months. Accounting for missed fills, it was impractical to assign a therapy step using a period shorter than 6 months. We identified steps in three 6-month periods: a single preindex period and two nonoverlapping postindex periods.
EPR3-preferred therapies for steps 3-4 differ in the dose of ICS used. For fluticasone/salmeterol (ICS ϩ LABA) medications, we assumed patients had low, medium, and high daily dosages if they filled prescriptions with strengths of 100/50 g, 250/50 g, and 500/50 g, respectively. For other medications we used information from claims (days of supply and quantity), from the National Drug Code reference table (strength and package size) and from the manufacturer (number of puffs per canister) to calculate the daily dosage for each claim. ICS claims were assigned as low, medium, or high dose based on this calculated For permission to copy go to www.copyright.com daily dose.
Step 6 requires "long-term use of OCSs," which we defined as a total supply of Ն60 days in a 6-month period. To internally validate the step assignment algorithm, we compared our assigned step with a validated claims-based measure of asthma risk 7 and with intensity of pulmonologist/allergist visits.
The primary study outcome was the proportion of patients with an increase in therapy step after they had evidence of lack of asthma control (either risk or impairment). We looked for evidence of increased step between the preindex period and either of the two postindex periods to allow time for the clinician(s) to react to a lack of control and for evidence of such a reaction to appear in claims. We accepted any increase in step from the preindex period to either postindex period as being consistent with EPR-3 guidelines, even if care later returned to baseline. Secondary outcomes included specialist visits and OCS use after the index event.
Statistical Methods
We reported descriptive statistics for baseline measures. Means with standard deviations were reported for continuous variables, and patient counts with percentages were reported for categorical variables. To test our claims-based algorithm for assigning step, we compared risk stratification, number of physician visits, and physician specialty across each step of care using chi-square and F-tests. To examine the response to poor control, we described increase in step, use of specialists, and use of OCS, stratified by baseline step. We used logistic regression models to identify which baseline characteristics were associated with an increased step. Separate logistic regression models were conducted for each preindex therapy step.
The baseline characteristics included in the logistic models were determined a priori and included age, gender, region, index events, risk stratification, usualcare physician specialty, any allergist or pulmonologist visits, number of physician visits, sinusitis, rhinitis, acute upper respiratory infection, cough, other asthmarelated comorbidity (including tonsillitis, conjunctivitis, or nasal polyposis), and number of chronic conditions. We reported adjusted odds ratios (OR) and their 95% confidence intervals.
In the main analysis, if a patient had both impairment and risk, we included both uncontrolled asthma events independently. In a sensitivity analysis, we included only the earlier of the two events. All data transformations and statistical analyses were performed using SAS Version 9.1 (SAS Institute, Cary, NC).
RESULTS
We identified 580,955 patients meeting our definition of asthma, most of whom (501,527) had no evidence of lack of control. After excluding 28,220 who did not meet the age criteria; 28,940 who were not continuously enrolled for 2 years; and 9,303 who had chronic obstructive pulmonary disease, emphysema, cystic fibrosis, pregnancy, or bronchopulmonary dysplasia, we had 18,343 episodes of uncontrolled asthma. The mean (ϮSD) patient age was 39.6 years (Ϯ14.6 years), half were between 35 and 54 years old, and 58.2% were women. Reflecting the geographic range of the claims database, all major regions of the country were represented: 34.1% of patients were from the Midwest, 10.5% were from the Northeast, 41.1% were from the South, and 14.4% were from the West (Table 1) . Patients in higher baseline steps were older (48.4 years in step 6 versus 37.6 years in step 1). Acute asthma-related comorbidities were common, with 40.0% having at least one claim for rhinitis, 36.7% for sinusitis, 22.9% for cough, and 20.6% for acute upper respiratory infection. Patients had a mean of 3.3 chronic conditions (including asthma). There were differences in comorbidity across step categories, with those in higher steps generally having more comorbidities (acute and chronic) than those in lower steps ( Table 2) .
The algorithm for step assignment classified 14,886 patients as steps [1] [2] [3] [4] [5] [6] . No asthma treatment was identified for 759 patients. An additional 2698 patients had treatment during the preindex period that was not consistent with any EPR3-based step. Most (65.3%) filled OCS prescriptions without any other asthma medication. The second largest group (26.8%) filled high-dose ICS but no LABA prescriptions.
We tested the internal validity of our algorithm with several comparisons among the patients assigned to steps 1-6. We used a validated, claims-based system to measure risk of exacerbation. 7 Twenty-six percent (n ϭ 3911) were assessed as having low risk, 61% (n ϭ 9116) were assessed as medium, and 12.5% (n ϭ 1859) were assessed as high. As steps increased, the proportion of patients classified as low risk decreased (35.3% of step 1 patients versus 0% of step 6 patients) and the proportion classified as high risk increased (10% of step 1 patients versus 33% of step 6 patients; Fig. 2) .
As further validation of our algorithm, we examined the relationship between assigned step and physician use. Primary care physicians were the usual-care physicians for 69.8% of patients, allergists for 9.6% of patients, and pulmonologists for 3.8% of patients. In the preindex year, patients had a mean of 4.8 primary care visits, 1.8 allergist visits, and 0.4 pulmonologist visits. Patients assigned to higher steps in the preindex period were more likely to have specialists as their usual-care physicians. Patients in higher steps also tended to have more specialist and more generalist visits than those in lower steps (Fig. 3) .
We classified 14,781 patients as steps 1-5 during the 6 months before they had evidence of poor control, and we examined the change in their care in the year after the index event. Patients at step 6 were ineligible to be stepped up and were not analyzed. Twenty-seven per- For permission to copy go to www.copyright.com cent were at a higher step of therapy during the postindex period than during the preindex period. We looked for other changes in care and found that 42.8% of patients had filled OCS prescriptions within 7 days of a physician visit during the postindex period. In addition, 33.8% of patients saw a specialist in the year after the index event.
The proportion of patients whose care changed in each of these ways varied by preindex step. Increasing step was more common for those at lower baseline steps: 41.3% of those in step 1 at baseline had an increase in step postindex, compared with 12.4% of those at step 5. Conversely, OCS prescriptions and specialist care both were more common with increasing baseline therapy step. OCS prescriptions were filled for 33.2% of those in step 1 and 57.0% in step 5. Twenty percent of step 1 patients visited a specialist after their index event compared with 52% of step 5 patients (Fig. 4) .
To control for baseline differences and to estimate the impact of various characteristics on the likelihood of having care stepped up, we conducted five logistic regression models, one for each preindex step. Separate models were conducted for each preindex step because exploratory models showed that behavior differed substantially across steps. Each model examined the effect of baseline variables on stepping up care.
For all steps, high-risk patients were more likely to step up in therapy than low-risk patients. The degree of increase in odds varied from an OR of 1.50 for step 2 to an OR of 11.4 for step 5. For most baseline steps, an increase in step was more likely among those whose evidence of lack of control came as a second OCS fill than a seventh SABA fill. There were no other consistent predictors of stepping up (Table 3) . In a sensitivity analysis, we only included the first uncontrolled asthma event for each patient. This analysis excluded the second uncontrolled event for 867 patients with evidence of both impairment and risk, leaving 17,476 unique patients. We repeated the regression models with this group, and the results were substantively unchanged from the main analysis.
DISCUSSION
In the current health care environment, evidencebased care has assumed a high profile. Clinicians are being admonished to eliminate errors and follow For permission to copy go to www.copyright.com Step 1 n ‫؍‬ 4678
Step 2 n ‫؍‬ 2475
Step 3 n ‫؍‬ 2255
Step 4 n ‫؍‬ 3697
Step 5 n ‫؍‬ 1676
Step best practices, such as those laid out in clinical practice guidelines. 8 At the health plan level, improving guideline adherence begins with measuring the extent to which practices diverge from those guidelines at baseline. This measurement process can be complex, particularly when using secondary data. Insurance claims lack the clinical detail used to make medical decisions, and researchers can not use them to determine if there are extenuating reasons for nonadherence to guidelines. However, experience with the National Committee for Quality Assurance's (NCQA) Health Care Effectiveness Data and Information Set suggests that measuring and reporting adherence to standards can noticeably improve care. 9 If claims-based measures of adherence are not available, more costly and time-consuming methods must be used, possibly reducing the chance that guideline adherence will be improved. We created a claims-based algorithm for grouping patients with evidence of poor control into the treatment steps defined in the 2007 NHLBI Asthma Guidelines. Our goal was to use this algorithm to test the current level of adherence with a key recommendation of EPR3: therapeutic intensity should increase in the presence of poor control. To validate it, we applied the algorithm in a Health Insurance Portability and Accountability Act-compliant administrative claims database and found greater use of specialist care in patients we identified as being at higher steps of therapy. Those identified as being at Step 1
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Preindex therapy step No. of physician visits among asthma patients with indicated baseline asthma risk For permission to copy go to www.copyright.com higher steps also had a greater risk of exacerbation as measured by a claims-based tool, a modification of which has been used in several recent studies.
7,10 -12
The combination of these findings gives us some confidence that our step assignment algorithm functioned as planned. Our data had no patient identifiers, so we could not validate our assignment with a review of medical records or survey. Such external validation would be extremely useful, and we are pursuing methods of conducting such studies. There were significant differences between the care received by patients with uncontrolled asthma and that recommended by EPR3. Of the patients who were classified as steps 1-5, only 28% had evidence that therapy was stepped up as recommended. Perhaps more concerning, the more severely ill patients were less likely than their lower-step counterparts to have recommended changes in medications and were instead more likely to have OCS prescriptions. Most step 5 patients filled an OCS prescription after they were shown to have inadequate control, but only 12% had the EPR3-recommended use of ICSs, LABAs, or omalizumab. Long-term reliance on OCSs alone may have serious clinical consequences. 2 Clinicians may need to become more comfortable increasing therapeutic intensity for patients at steps 3-5 who are already using ICS/LABA inhalers. Our findings of potential undertreatment are consistent with recent studies showing that adults whose asthma was not well controlled in the past are at higher risk of future poor control. 10, 11, 13 Asthma specialist care appears to be underused, and this may have contributed to the underuse of appropriate therapy for the sickest patients. EPR3 recommends specialist consultation at step 4 or higher, but fewer than one-half of these patients had appropriate specialist visits. Nonspecialists may be more comfortable moving from step 2 to 3 (which can be done by adding low-dose combination ICS/ LABA therapy) than moving from step 4 to 5 (which requires the use of high-dose ICS). A survey of primary care physicians found that a substantial minority held views of controller use that were inconsistent with guidelines.
14 Because the guidelines are new, it is difficult to compare our findings directly with those in prior studies. In a comprehensive review of U.S. health care quality, Schuster and colleagues found that asthma quality indicators were followed in 30 -45% of cases. 8 A recent study of asthma care in ED found 67% concordance of care with 12 specific guideline elements. 15 Commercial health plans report 92.3% compliance with the Health Health Care Effectiveness Data and Information Set Effectiveness Data and Information Set asthma measure that requires prescription of at least one controller medication. 9 This study had limitations. EPR3 recommends that step assignment be clinically based, but clinical detail is extremely limited in administrative claims data. If we systematically misidentified steps, our findings would be biased. We compared our step assignment with several variables and found a reasonable association, but we did not perform a "gold standard" comparison with clinicians or medical records. All of the usual limitations associated with using administrative claims data (e.g., miscoding, not applicable to noncommercially insured populations) apply to our study. Even with those limitations, our methodology can be used in future claims analyses to track changes in patterns of care. Step 1
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Our goal was to describe the current level of compliance to determine changes needed to improve asthma care. We conclude that current asthma care will have to change significantly to be brought in line with the 2007 NHLBI Asthma Guidelines. Aligning patients' asthma therapy with guidelines, including more ICS and less OCS use, would improve the health of asthma patients. With concerted effort, increased guideline adherence is achievable. The National Committee for Quality Assurance reports a Ͼ40% increase in adherence to the asthma measure over 6 years. 9 We reviewed care that occurred before EPR3 was released, so clinicians could not have been trying to comply with the guidelines and should not be faulted for these findings. Our claims-based algorithm for step assignment may make ongoing studies of the quality of asthma care easier to conduct.
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